The statement “Brain damage is possible even after a single dose. The EMA has ordered the immediate recall of the drugs” appears to refer to a real safety issue involving certain medicines, but viral posts often leave out important details. (European Medicines Agency (EMA))
The European Medicines Agency (EMA) reviewed levamisole-containing medicines and confirmed that they can rarely cause leukoencephalopathy, a serious condition involving damage to the brain’s white matter. The review found that this reaction can occur after a single dose and may appear from one day to several months later. (European Medicines Agency (EMA))
Symptoms that need medical attention may include:
- Muscle weakness
- Difficulty speaking
- Confusion or changes in thinking
- Problems with coordination or movement
- Other neurological changes (European Medicines Agency (EMA))
EMA recommended withdrawal of levamisole medicines from the EU market because the risks were considered to outweigh the benefits for treating certain parasitic worm infections, where alternative treatments are available. (European Medicines Agency (EMA))
If you have taken a medicine containing levamisole and are concerned, do not panic—contact a healthcare professional for advice, especially if you notice any neurological symptoms. Do not stop prescribed medicines without discussing it with your doctor. (European Medicines Agency (EMA))
When sharing or reading health alerts online, check the specific drug name, country, and official regulator notice—a headline alone may not apply to all medicines or all patients.
